

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of
M. Egawa, et al.

Serial No.: To Be Assigned

Art Unit: To Be Assigned

Filed: Concurrently herewith

Examiner: To Be Assigned

For: METHOD OF TREATING ENVIRONMENTAL STRESS

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

After assigning a serial number to the above-captioned application and before calculating the fee, kindly undertake the following changes:

IN THE SPECIFICATION:

On page 21, kindly substitute the following paragraph for the third paragraph therein:

--After the culture was completed, the medium was removed and replaced with PBS (-) and the ultraweak chemiluminescence from the aforementioned human fibroblast cells adhered to the bottom of the Petri dish was measured for 10 minutes using a chemiluminescence detector (model CLD-110 from Tohoku Electronic Industries Co., Ltd.). The number of photoelectrons generated

during this time was converted to an electric voltage to obtain the normal value of the ultraweak chemiluminescence.--

On page 23, please replace the original 2nd paragraph therein with the following paragraph:

--An 1.0 wt% aqueous solution of each of 1) α -tocopherol, 2) β -carotene, 3) thiotaurine (from Sogo Pharmaceutical Co., Ltd.), 4) hypotaurine (from Sogo Pharmaceutical Co., Ltd.), 5) glutathione, 6) tannin, 7) vitamin C derivative (L-ascorbic acid phosphate (magnesium)), 8) thiotaurine + malic acid, 9) hypotaurine + malic acid and 10) glutathione + malic acid (when combined with malic acid, 1.0 wt% of malic acid was contained as well as 1.0 wt% of the antioxidant) was applied on the medial aspect of the human forearm. For each of these, the normal value of the corneum moisture content was measured. For the controls, "the group with no drug applied" and "the non-exposure group", which was not exposed to tobacco smoke or exhaust gas, were used.--

On pages 25 and 26, please replace the paragraph bridging same with the following paragraph:

--The results are shown in FIG. 3. In FIG. 3, the vertical axis represents the intensity of the ultraweak chemiluminescence (a relative value (%) assuming the normal value without anything applied to be 100) and along the horizontal axis are the essential ingredients of the liniment composition for preventing

environmental stress of the present invention for which the testing was conducted. Among these essential ingredients, the vitamin C derivative refers to the aforementioned L-ascorbic acid phosphate (magnesium).--

IN THE CLAIMS:

Kindly cancel claims 5-12 and 17-19.

REMARKS

Claims 5-12 and 17-19 have been cancelled. Claims 1-4 and 13-16, which are directed to treating environmental stress on the skin due to contact with tobacco smoke, remain in the application. In addition, the specification has been amended so as to conform the specification to the present specification in the parent U.S. application No. 09/478,882.

It is respectfully submitted that this application is now in condition for examination on the merits and early action and allowance thereof is accordingly respectfully requested.

Respectfully submitted,

TOWNSEND & BANTA

Donald E. Townsend, Jr.

Donald E. Townsend, Jr.
Reg. No. 43,198

Date: November 21, 2001

TOWNSEND & BANTA
1225 Eye Street, N.W.
Suite 500, #50028
Washington, D.C. 20005
(202) 682-4727

MARKED-UP VERSIONS OF AMENDED SPECIFICATION PARAGRAPHS:

On page 21, kindly substitute the following paragraph for the third paragraph therein:

--After the culture was completed, the medium was removed and replaced with PBS (-) and the ultraweak chemiluminescence from the aforementioned human fibroblast cells adhered to the bottom of the Petri dish was measured for 10 minutes using a chemiluminescence detector (model CLD-110 from Tohoku Electronic Industries Co., Ltd.). The number of photoelectrons generated during this time was converted to an electric voltage to obtain the [blank] normal value of the ultraweak chemiluminescence.--

On page 23, please replace the original 2nd paragraph therein with the following paragraph:

--An 1.0 wt% aqueous solution of each of 1) α -tocopherol, 2) β -carotene, 3) thiotaurine (from Sogo Pharmaceutical Co., Ltd.), 4) hypotaurine (from Sogo Pharmaceutical Co., Ltd.), 5) glutathione, 6) tannin, 7) vitamin C derivative [[L-ascorbic acid phosphate (magnesium)[]]], 8) thiotaurine + malic acid, 9) hypotaurine + malic acid and 10) glutathione + malic acid (when combined with malic acid, 1.0 wt% of malic acid was contained as well as 1.0 wt% of the antioxidant) was applied on the medial aspect of the human forearm. For each of these, the [blank] normal value of the corneum

moisture content was measured. For the controls, "the group with no drug applied" and "the non-exposure group", which was not exposed to tobacco smoke or exhaust gas, were used.--

On pages 25 and 26, please replace the paragraph bridging same with the following paragraph:

--The results are shown in FIG. 3. In FIG. 3, the vertical axis represents the intensity of the ultraweak chemiluminescence [[] (a relative value (%) assuming the [blank] normal value without anything applied to be 100[[]]) and along the horizontal axis are the essential ingredients of the liniment composition for preventing environmental stress of the present invention for which the testing was conducted. Among these essential ingredients, the vitamin C derivative refers to the aforementioned L-ascorbic acid phosphate (magnesium).--

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

M. Egawa, et al.

Serial No.: To Be Assigned

Art Unit: To Be Assigned

Filed: Concurrently herewith

Examiner: To Be Assigned

For: Method Of Treating Environmental Stress

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In compliance with the dictates of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants hereby submit an Information Disclosure Statement.

It is respectfully requested that the Examiner consider the attached reference and indicate such consideration by enclosing an appropriately initialed copy of the enclosed form PTO-1449 with the next communication from the Patent Office.

It is believed that no fee is required for the filing of this Information Disclosure Statement, as this IDS is being filed with a new application. However, the Commissioner is hereby authorized to charge any fee necessary for the filing of this document to Deposit Account No. 20-1424.

2